Caribou Biosciences (CRBU) Accumulated Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Accumulated Expenses data on file, last reported at $13.9 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 30.16% year-over-year to $13.9 million in Q1 2026; TTM through Mar 2026 was $13.9 million, a 30.16% decrease from a year earlier, with the FY2025 full-year figure at $16.5 million, down 30.0% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $13.9 million, down from $16.5 million in the prior quarter.
• Over the last five years, Accumulated Expenses for CRBU reached as high as $25.4 million in Q3 2024 and fell as low as $100000.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $16.5 million across 5 years, with a median of $18.2 million in 2023.
• On a YoY basis, Accumulated Expenses climbed as much as 14637900.0% in 2022 and fell as far as 98.5% in 2022.
• Year by year, Accumulated Expenses stood at $16.1 million in 2022, then jumped by 31.44% to $21.1 million in 2023, then advanced by 11.76% to $23.6 million in 2024, then fell by 30.0% to $16.5 million in 2025, then decreased by 16.0% to $13.9 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $13.9 million in Q1 2026, $16.5 million in Q4 2025, and $19.3 million in Q3 2025.